key: cord-0759836-ip9vzkea
authors: Horii, Hiroshi; Kamada, Keisuke; Nakakubo, Sho; Yamashita, Yu; Nakamura, Junichi; Nasuhara, Yasuyuki; Konno, Satoshi
title: Rapidly progressive organizing pneumonia associated with COVID-19
date: 2020-11-18
journal: Respir Med Case Rep
DOI: 10.1016/j.rmcr.2020.101295
sha: adb666683d0d98ccc09fee9e16dd7bf09b9c20a0
doc_id: 759836
cord_uid: ip9vzkea

We report a case of clinically diagnosed secondary organizing pneumonia (SOP) associated with coronavirus disease 2019 (COVID-19). A 70-year-old woman who had been diagnosed with COVID-19 was admitted to Hokkaido University Hospital. Although her fever, cough, dyspnea, and serum C-reactive protein levels improved, she developed rapidly progressive respiratory failure and computed tomography revealed the development of bilateral lung consolidation. Her dyspnea was relieved, and her oxygenation levels and radiological findings improved after commencing corticosteroid treatment. Blood biomarkers for interstitial lung disease, Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D), showed different responses during the clinical course of her disease. Evaluation of serial changes in levels of KL-6 and SP-D may help diagnose and monitor COVID-19-associated organizing pneumonia (OP). Clinicians should be aware that SOP can develop in response to COVID-19 and that these patients may benefit from the use of steroids.

We report a case of clinically diagnosed secondary organizing pneumonia (SOP) associated with 33 coronavirus disease 2019 . A 70-year-old woman who had been diagnosed with COVID-19 34 was admitted to Hokkaido University Hospital. Although her fever, cough, dyspnea, and serum 35 C-reactive protein levels improved, she developed rapidly progressive respiratory failure and 36 computed tomography revealed the development of bilateral lung consolidation. Her dyspnea was 37 relieved, and her oxygenation levels and radiological findings improved after commencing 38 corticosteroid treatment. Blood biomarkers for interstitial lung disease, Krebs von den Lungen-6 (KL- 

Organizing pneumonia (OP) is a pulmonary inflammatory condition that occurs in certain clinical 49 settings and may be associated with connective tissue disorders, infectious diseases, or organ 50 transplantations, or it could be drug-related [1] . The clinical and radiographic findings, treatment 51 response, and prognosis in patients with both cryptogenic OP and secondary OP (SOP) are similar and 52 nonspecific [2] . Cytomegalovirus, influenza virus, parainfluenza virus, human immunodeficiency virus 53 and herpesvirus infections have been reported to cause SOP [1] . There have been no reports of SOP 54 triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The primary 55 computed tomography (CT) finding in early-stage coronavirus disease 2019 (COVID-19) is ground-56 glass opacities (GGOs) in the lungs, that may change to consolidations in approximately 9 days [3] , 57 making it challenging to differentiate COVID-19 pneumonia from SOP based on the imaging findings 58 alone. 59

Here we report a case of COVID-19-associated SOP in which corticosteroid treatment was effective at 60 relieving the dyspnea and improving oxygenation. Among the blood biomarkers for interstitial lung 61 disease, Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D) were assessed, which have 62 been widely used in clinical practice [4] . Assessment of serial changes in serum biomarkers, including 63 KL-6 and SP-D, is useful in the diagnosis of SOP. 64

A 70-year-old woman, who had been diagnosed with COVID-19 by polymerase chain reaction (PCR) 66 testing of nasopharyngeal swab samples for SARS-CoV-2, was admitted to Hokkaido University 67

Hospital for further treatment. She had never smoked and had an unremarkable medical history. She 68 presented with a one-week history of cough, dyspnea, loss of appetite, and a high fever. On 69 admission, her body temperature was 37.9°C, blood pressure was 136/67 mmHg, heart rate was 88 70 beats/min, respiratory rate was 29 breaths/min, and her percutaneous oxygen saturation (SpO 2 ) was 71 95% while breathing 5 L/min of oxygen with an oxygen mask. The laboratory findings included 72 elevated levels of serum C-reactive protein, lactate dehydrogenase, and ferritin; normal levels of 73 procalcitonin, D-dimer, KL-6, and SP-D; and reduced levels of eosinophils and lymphocytes (Table 1) . 74 CT imaging revealed bilateral GGOs with superimposed intralobular reticulations in a crazy-paving 75 pattern in both lung fields ( Figure 1A ). There were no findings suggesting pulmonary embolism, 76 purulent sputum or infiltrative shadows, and no findings suggesting bacterial infection. Therefore, no 77 antibiotics were administered, and no blood or sputum culture was performed. Additionally, the 78 patient had no lower leg edema or any signs of congestive heart failure. Based on these findings, we 79 commenced treatment with favipiravir (1600 mg/day), ciclesonide (1200 μg/day), and nafamostat 80 (300 mg/day), as a for SARS-CoV-2 infection. 81

The patient's fever, cough, dyspnea, and serum C-reactive protein levels improved after starting the 82 treatment, and on Day 8 of hospitalization, her SpO 2 was 95% while breathing 2 L/min of oxygen with 83 a nasal cannula. However, on Day 10, she developed rapidly progressive respiratory failure, and her 84 SpO 2 dropped to 94% while breathing 10 L/min oxygen using a reservoir mask. CT imaging revealed 85 that the bilateral GGOs observed earlier had progressed to lung consolidation, and there were no 86 new GGOs ( Figure 1B) . Furthermore, her serum SP-D level was higher than the level on admission. 87

Clinically, COVID-19-associated SOP was suspected, and systemic corticosteroid therapy (prednisolone 88 1 mg/kg/day) was initiated. Three days after starting corticosteroid therapy (day 13), her oxygenation 89 level improved dramatically, and SpO 2 was 94% while breathing 1 L/min oxygen with a nasal cannula. 90 CT imaging performed on day 7 after starting corticosteroid therapy (day 17) revealed less intense 91 lung lesions than previous evaluated ( Figure 1C ). Her serum levels of SP-D and surfactant protein A 92 (SP-A) had also decreased to within the normal range. On day 18 and 19 after hopitalization, a PCR 93 test of a nasopharyngeal swab sample was negative for SARS-CoV-2. Serial changes in serum 94 biomarkers evaluated throughout her hospital stay are shown in Table 1 and Figure 1 . Prednisolone 95 was tapered down to 30 mg, and she was discharged day 38 after admission. After discharge, 96 prednisolone was tapered down to 20 mg for 20 days, 10 mg for 14 days and 5 mg for 14 days, and 97 discontinued thereafter. In subsequent follow-up visits, no increase in KL-6 or SP-D, and no shadows 98 exacerbations were observed. 99

To the best of our knowledge, this is the first report to document serial changes in radiologic findings 101 and laboratory biomarkers in a patient with COVID-19-associated SOP. The patient showed clinical 102 improvement on commencing treatment with favipiravir, ciclesonide, and nafamostat for 103 SARS-CoV-2 infection, but subsequently developed rapidly progressive hypoxemia and required a 104 high dose of oxygen. There were no signs of a secondary bacterial infection or pulmonary embolism 105 or heart failure, and her general condition was good relative to her oxygen demand. She improved 106 clinically soon after starting steroid treatment. 107

Chest CT performed on day 7 of hospitalization revealed a notable reduction in lung volume and 108 increased intensity of the diffuse bilateral GGOs, observed on admission, but no new GGOs in other 109 lung fields; consistent with previous reports of serial CT findings in COVID-19 patients [3] . Lung tissue 110 biopsy is necessary for accurate diagnosis of OP, but bronchoscopy is a high-risk procedure 111 associated with a high level of aerosol generation and is challenging to perform in COVID-19 patients. 112

Although we did not obtain definitive pathological confirmation in this case, we based our diagnosis 113 of SOP on the clinical observations (bimodal clinical course of the apparent re-exacerbation of 114 oxygen demand once improved, which is atypical for COVID-19 alone), elevated SP-D levels, 115 radiological findings, and the effectiveness of systemic corticosteroids in promoting clinical and 116 radiographic resolution. There was no discrepancy with the clinical and radiographic findings of SOP 117 presented in previous reports [2] . 118

Dexamethasone and other steroids have been reported to be effective for the treatment of COVID-119 19 [5] [6] , but it is not known which cases benefit the most. Although it was difficult to distinguish SOP 120 from the natural history of COVID-19 in this patient, her initial improvement followed by worsening 121 of her clinical condition, was atypical of the usual course of COVID-19. Steroid therapy is known to 122 worsen the prognosis in influenza virus pneumonia [7] , but the cause of the variable therapeutic 123 response in different types of viral infection is unknown. Future cases demonstrating SOP as more 124 common in COVID-19 than in other viral infections may explain the effectiveness of steroids in 125 treating COVID-19. 126

The serial changes in several important serum biomarkers for interstitial lung disease are of 127 relevance in this case. OP with elevated serum KL-6 may be more severe and unstable [8] ; require 128 treatment with prednisolone [9] , and has a higher frequency of relapse [10] compared to OP with 129 normal serum KL-6. Patients with OP and elevated serum levels of SP-D had significantly increased 130 serum KL-6 level and a significantly higher relapse rate than those with a normal level of SP-D [11] . 131

Our patient had elevated SP-D levels, but her KL-6 levels were within the reference range, and her 132 SP-D level rapidly decreased after initiating steroid administration. There are several possible 133 explanations for this paradoxical dissociation, which is related to the functional differences between 134 these proteins. Both serum SP-A and SP-D levels are associated with the extent of alveolitis (a 135 reversible change) [12] . On the other hand, increased serum levels of KL-6 might be related to 136 irreversible alveolar cell damage [13] . Discordant serum levels of these biomarkers has also been 137 observed in cases of multifocal micronodular pneumocyte hyperplasia, which is characterized by type 138 II alveolar cell proliferation, but not with alveolar cell damage [14] . Further evaluation of serial levels 139 of each of these three biomarkers may be helpful for identifying and monitoring the activity of 140 COVID-19-associated SOP. 141

In summary, we report a case of COVID-19-associated SOP with serial changes in radiographic and 143 laboratory findings. Physicians should be aware that patients with COVID-19 can develop SOP in 144 response to SARS-CoV-2 infection and that they may benefit from the use of steroids. 145 Acknowledgements 147 Consent for publication 148 Written informed consent was obtained from the patient. 149 

Organizing pneumonia

Cryptogenic and secondary organizing pneumonia: clinical presentation, radiographic findings, treatment response, and prognosis

Time Course of lung changes at chest CT during recovery from Coronavirus Disease 2019 (COVID-19)

Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases

Dexamethasone in hospitalized patients with Covid-19 -Preliminary report

for the Metcovid Team, 2020. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial

Corticosteroids as adjunctive therapy in the treatment of influenza

Clinical significance of serum KL-6 levels in organizing pneumonia proven by lung biopsy

Clinical characteristics classified by the serum KL-6 level in patients with organizing pneumonia

Comparison of pulmonary CT findings and serum KL-6 levels in patients with cryptogenic organizing pneumonia, B

A retrospective clinical research of relapsed organizing pneumonia

Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. American journal of respiratory and critical care medicine

KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease

Clinical Course of Histologically Proven Multifocal Micronodular Pneumocyte Hyperplasia in Tuberous Sclerosis Complex: A Case Series and Comparison with Lymphangiomyomatosis, Respiration

The authors have no conflicts of interest to declare.